Intellia Therapeutics (NTLA) Income from Continuing Operations (2015 - 2026)
Intellia Therapeutics (NTLA) reported Income from Continuing Operations of 95327000.0 for Q1 2026, up 15.04% year-over-year from 82863246.4 in Q1 2025, and down 3.35% on a QoQ basis from 92234000.0 in Q4 2025.
Intellia Therapeutics (NTLA) has 12 years of Income from Continuing Operations data on file, last reported at 95327000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 15.04% year-over-year to 95327000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 394918000.0 (up 20.59% YoY) and the FY2025 annual result came in at 411795000.0, up 15.35% from the prior year.
- Income from Continuing Operations fell to 95327000.0 in Q1 2026 per NTLA's latest filing, from 92234000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 92234000.0 in Q4 2025 and bottomed at 143706000.0 in Q1 2022.
- The 5-year median for Income from Continuing Operations is 104763000.0 (2025), against an average of 112274058.82.
- The widest annual swing landed in 2022, when Income from Continuing Operations tumbled 211.02%; it then soared 30.43% in 2023.
- Tracing NTLA's Income from Continuing Operations over 5 years: stood at 104733000.0 in 2022, then dropped by 21.67% to 127433000.0 in 2023, then gained by 1.27% to 125816000.0 in 2024, then increased by 26.69% to 92234000.0 in 2025, then declined by 3.35% to 95327000.0 in 2026.
- Per Business Quant, the three latest NTLA Income from Continuing Operations figures stand at 95327000.0 (Q1 2026), 92234000.0 (Q4 2025), and 104763000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - | -95.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -95.33 Mn |
| Dec 31, 2025 | -92.23 Mn |
| Sep 30, 2025 | -104.76 Mn |
| Jun 30, 2025 | -102.59 Mn |
| Mar 31, 2025 | -112.20 Mn |
| Dec 31, 2024 | -125.82 Mn |
| Sep 30, 2024 | -132.65 Mn |
| Jun 30, 2024 | -126.62 Mn |
| Mar 31, 2024 | -101.37 Mn |
| Dec 31, 2023 | -127.43 Mn |
| Sep 30, 2023 | -118.37 Mn |
| Jun 30, 2023 | -119.68 Mn |
| Mar 31, 2023 | -99.98 Mn |
| Dec 31, 2022 | -104.73 Mn |
| Sep 30, 2022 | -103.59 Mn |
| Jun 30, 2022 | -97.60 Mn |
| Mar 31, 2022 | -143.71 Mn |
| Dec 31, 2021 | -79.91 Mn |
| Sep 30, 2021 | -71.64 Mn |
| Jun 30, 2021 | -68.81 Mn |
| Mar 31, 2021 | -46.21 Mn |
| Dec 31, 2020 | -42.19 Mn |
| Sep 30, 2020 | -27.84 Mn |
| Jun 30, 2020 | -32.39 Mn |
| Mar 31, 2020 | -31.81 Mn |
| Dec 31, 2019 | -28.28 Mn |
| Sep 30, 2019 | -23.63 Mn |
| Jun 30, 2019 | -25.68 Mn |
| Mar 31, 2019 | -21.94 Mn |
| Dec 31, 2018 | -19.07 Mn |
| Sep 30, 2018 | -22.70 Mn |
| Jun 30, 2018 | -22.22 Mn |
| Mar 31, 2018 | -21.36 Mn |
| Dec 31, 2017 | -23.96 Mn |
| Sep 30, 2017 | -15.36 Mn |
| Jun 30, 2017 | -15.59 Mn |
| Mar 31, 2017 | -12.63 Mn |
| Dec 31, 2016 | -10.56 Mn |
| Sep 30, 2016 | -7.48 Mn |
| Jun 30, 2016 | -6.90 Mn |
| Mar 31, 2016 | -6.69 Mn |
| Dec 31, 2015 | -5.25 Mn |
| Sep 30, 2015 | -3.02 Mn |
| Jun 30, 2015 | -3.04 Mn |
| Mar 31, 2015 | -1.09 Mn |